Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00050414CT.gov A Study of Trabectedin in Patients With Advanced Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endocrine Gland Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B · 57 |
| Irinotecan | Xiaoxiang Chen | P2 | BB |
| Trabectedin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Denosumab | Amgen | P2 | B |
| Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer | NantCell, Inc. | P3 | CCC |
| Teonanacatl | University Health Network, Toronto | P2 | CCC |
| Niraparib | Xiaoxiang Chen | P2 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
| Entinostat | Syndax Pharmaceuticals | P1 | CCC |
+4 more in the Endocrine Gland Neoplasm cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanXiaoxiang ChenBB
- TrabectedinJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- DenosumabAmgenB
- Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, DimerNantCell, Inc.CCC
- TeonanacatlUniversity Health Network, TorontoCCC
Citation
Floatz Terminal. Dexasone in Endocrine Gland Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-endocrine-gland-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →